Understanding why eligible patients with cancer decline clinical trial participation is critical to developing targeted accrual interventions. DCP-001 is a National Cancer Institute (NCI) Division of Cancer Prevention protocol within the NCI Community Oncology Research Program (NCORP). The protocol systematically...
J. Kahn, M. Beauchemin, Erik Harden et al.· Cancer Epidemiology, Biomark...· 0 citations
178
Background:
Delay in time from muscle invasive bladder cancer (MIBC) diagnosis to neoadjuvant chemotherapy (NACT) > 60 days, can negatively impact cancer related outcomes. However, the underlying causes of these delays remain poorly characterized, underscoring the need for further investigation.
Methods:...
Margaux Wooster, Abha Kulkarni, R. Raghunathan et al.· JCO Oncology Practice· 0 citations
134
Background:
The geographic source of patient enrollments is integral to the interpretation and generalizability of cancer clinical trial findings. For U.S. patients and policymakers, site location may affect how well findings apply to U.S. populations and care settings. However, comparisons of geographic pa...
J. Unger, Hong Xiao, Michael Leblanc et al.· JCO Oncology Practice· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
